文献速递骨质疏松与钙磷/甲状旁腺

PI3K/AKT/mTOR通路激活与甲状旁腺癌恶性程度及不良预后相关

PI3K/AKT/mTOR Activation Is Associated With Malignant Severity and Poorer Prognosis in Parathyroid Carcinomas.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

研究纳入双中心64例甲状旁腺癌患者及29例对照,分析mTORC1活性及PI3K/AKT/mTOR通路和CDC73基因变异。48.5%的甲状旁腺癌为高mTORC1活性,仅22.7%的甲状旁腺腺瘤/非典型甲状旁腺肿瘤对照达此标准;16/66份甲状旁腺癌样本检出PI3K/AKT/mTOR变异,该变异组无病生存和总生存显著更差。

要点

  • 48.5%的甲状旁腺癌呈现高mTORC1活性,高于甲状旁腺腺瘤/非典型甲状旁腺肿瘤组的22.7%。
  • 16/66(24.2%)份甲状旁腺癌样本检出PI3K/AKT/mTOR变异,多数缺乏CDC73变异。
  • PI3K/AKT/mTOR变异组血清PTH、碱性磷酸酶和肌酐更高,无病生存和总生存显著更差。

核心结论

  • 甲状旁腺癌中PI3K/AKT/mTOR通路激活提示其恶性程度,可能导致不良结局。

研究设计与样本

  • 在10年期间从双中心招募64例甲状旁腺癌患者和29例对照(包括非典型甲状旁腺肿瘤、甲状旁腺腺瘤和正常甲状旁腺组织)。
  • 对64例甲状旁腺癌患者和29例对照分析mTORC1活性,对66份可用的甲状旁腺癌肿瘤组织行PI3K/AKT/mTOR通路基因(PIK3CA、PTEN、MTOR、TSC1、TSC2)和CDC73检测。
  • 随访时间长达117个月。

主要发现

  • 甲状旁腺肿瘤中mTORC1活性存在肿瘤间异质性。
  • 免疫组化染色显示甲状旁腺癌患者的mTORC1活性显著高于对照。
  • 48.5%的甲状旁腺癌肿瘤被分类为「高mTORC1」(高于预设阈值),而甲状旁腺腺瘤/非典型甲状旁腺肿瘤组仅22.7%的肿瘤符合该标准。
  • 16/66(24.2%)份甲状旁腺癌样本检出PI3K/AKT/mTOR变异,其中多数缺乏CDC73变异。
  • 有PI3K/AKT/mTOR变异的甲状旁腺癌mTORC1活性高于无变异者;与无任何靶向变异者相比,PI3K/AKT/mTOR变异组血清PTH、碱性磷酸酶和肌酐水平更高,且无病生存(P < .001)和总生存(P < .01)显著更差。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT AND OBJECTIVE: Parathyroid carcinoma (PCa) is a rare endocrine neoplasm known for its high recurrence. The specific molecular properties influencing the prognosis of PCa remain largely elusive. The present study was designed to explore the significance of PI3K/AKT/mTOR activation in PCa. METHODS: Over a 10-year period, 64 PCa patients were recruited from dual centers. We analyzed mechanistic target of rapamycin complex I (mTORC1) activity in 64 PCa patients and 29 controls, comprising atypical parathyroid tumor (APT), parathyroid adenoma (PAd), and normal parathyroid tissues. A panel of selected genes targeting the PI3K/AKT/mTOR pathway (PIK3CA, PTEN, MTOR, TSC1, and TSC2) and CDC73 was performed in 66 available tumor tissues from 64 patients with PCa. Follow-up lasted up to 117 months. RESULTS: There was intertumoral heterogeneity in mTORC1 activity in parathyroid tumors. Notably, we observed significantly elevated mTORC1 activity in PCa patients compared with controls, as assessed by immunohistochemical staining of tissue sections. Further analysis showed that 48.5% of PCa tumors were classified as "high mTORC1" (above the predefined threshold), while only 22.7% of tumors in the PAd/APT group met this criterion. Additionally, we detected PI3K/AKT/mTOR variants in 16/66 (24.2%) PCa samples, with the majority lacking CDC73 variants. Higher mTORC1 activity was noted in PCa with PI3K/AKT/mTOR variants than in those without. Compared with those without any targeted variants, the PI3K/AKT/mTOR-mutated group presented higher levels of serum PTH, alkaline phosphatase, and creatinine and was associated with significantly lower disease-free survival (DFS) and overall survival (OS) (DFS, P < .001; OS, P < .01). CONCLUSION: Our findings highlight that the activation of the PI3K/AKT/mTOR pathyway in PCa patients suggests their degree of malignancy, possibly leading to poor outcomes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Song JX, Dong YQ, Han RL, et al. PI3K/AKT/mTOR Activation Is Associated With Malignant Severity and Poorer Prognosis in Parathyroid Carcinomas. J Clin Endocrinol Metab. 2025. PMID: 39829129. doi:10.1210/clinem/dgaf042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。